
MapLight Therapeutics fell 49.6% from $13.69 to $6.90, behind the S&P 500's +11.2%. Its worst day was Jul 27 (−72.9%), and its low came Nov 5 at $6.22.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-37.18 missed the $-1.36 estimate on $0.00 revenue.
+8.4% · S&P 500 +0.1%
EPS of $-2.47 missed the $-0.92 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+6.0% · S&P 500 −1.8%
MapLight Therapeutics shares rose 21.3%, while the S&P 500 rose 0.6%.
+21.3% · S&P 500 +0.6%
EPS of $-1.34 missed the $-1.08 estimate on $0.00 revenue.
−1.9% · S&P 500 −1.2%
MapLight Therapeutics closed at its highest level of the year, 190.7% above where the year started.
+3.3% · S&P 500 +0.8%
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with
−72.9%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-1.32 beat the $-1.33 estimate on $0.00 revenue.
+1.5% · S&P 500 −0.2%
MapLight Therapeutics closed at its lowest level of the year, 54.6% below where the year started.
−7.3% · S&P 500 −4.4%
EPS of $-0.97 beat the $-1.13 estimate on $0.00 revenue.
−4.8% · S&P 500 −1.9%
Where it ended: a close of $6.90 on Nov 16, 2026.
Nothing in the past 12 months.
All MPLT dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MPLT and SPY from Benzinga historical bars. Not investment advice.